Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152074 | 0.89 | TDP1 (0.56) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL24089506 | 0.89 | TDP1 (0.63) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL8683110 | 0.88 | MAPK1 (0.54) | TDP1MAPK1EPHX2HRH3RARB | |
| SCHEMBL8120575 | 0.86 | TDP1 (0.53) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL26501101 | 0.85 | ACACB (0.49) | TDP1S1PR1S1PR5LMNASMN1; SMN2 | |
| SCHEMBL23966332 | 0.85 | TDP1 (0.59) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL14668123 | 0.85 | HRH3 (0.68) | HRH3SMN1; SMN2 | |
| 1,4-Diisopentoxybenzene SCHEMBL2846102 | 0.84 | TDP1 (0.79) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL27805471 | 0.84 | TDP1 (0.58) | TDP1MAPK1EPHX2S1PR1S1PR5 | |
| SCHEMBL27773084 | 0.84 | TDP1 (0.58) | TDP1MAPK1EPHX2S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | TDP1 2933/4885MAPK1 2171/4885EPHX2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.